Protection of gut microbiome from antibiotics: development of a vancomycin-specific adsorbent with high adsorption capacity.
adsorbent
antibiotic
dysbiosis
microbiome
microparticle
Journal
Bioscience of microbiota, food and health
ISSN: 2186-6953
Titre abrégé: Biosci Microbiota Food Health
Pays: Japan
ID NLM: 101578264
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
01
2020
accepted:
14
02
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
ppublish
Résumé
The fraction of administered antibiotics that reach the cecum and colon causes dysbiosis of the gut microbiome, resulting in various diseases. Protection of the gut microbiome from antibiotics using antibiotic adsorbents in the cecum and colon is a promising method to overcome this issue. Previously, activated charcoal (AC) has been reported to protect the gut microbiome of host animals. AC is an adsorbent that is widely used to capture toxic compounds and overdosed drugs in the gastrointestinal tract. The specificity of adsorbents for antibiotics is critical to avoid the risk of unexpected side effects caused by nonspecific adsorption of biological compounds in the intestinal fluid, such as bile acids and essential micronutrients. Here, we have developed specific adsorbents for vancomycin (VCM), which is known to cause gut dysbiosis. The adsorbents were composed of polyethyleneglycol-based microparticles (MPs) in which a specific ligand for VCM, D-Ala-D-Ala-OH, was attached via dendrons of D-lysine to raise the content of the ligand in the MPs. The MPs successfully protected
Identifiants
pubmed: 32775131
doi: 10.12938/bmfh.2020-002
pii: 2020-002
pmc: PMC7392918
doi:
Types de publication
Journal Article
Langues
eng
Pagination
128-136Informations de copyright
©2020 BMFH Press.
Références
Mucosal Immunol. 2017 Jan;10(1):18-26
pubmed: 27554295
J Control Release. 2013 Jan 28;165(2):139-45
pubmed: 23127508
Front Cell Infect Microbiol. 2019 Apr 24;9:99
pubmed: 31069173
Cell. 2014 Mar 27;157(1):121-41
pubmed: 24679531
Bioorg Med Chem Lett. 2007 Nov 1;17(21):5772-6
pubmed: 17827001
Sci Transl Med. 2018 Oct 24;10(464):
pubmed: 30355801
Pharm Res. 2008 Mar;25(3):667-71
pubmed: 17939018
J Pharm Pharmacol. 1995 Nov;47(11):901-6
pubmed: 8708983
Antimicrob Agents Chemother. 2004 Jan;48(1):75-9
pubmed: 14693521
Gastroenterology. 2015 Oct;149(4):883-5.e9
pubmed: 26164495
Eur J Pharm Sci. 2010 Oct 9;41(2):281-8
pubmed: 20599502
PLoS One. 2012;7(9):e44328
pubmed: 22957064
J Infect Dis. 2018 Jan 30;217(4):628-636
pubmed: 29186529
Nature. 1978 Jan 19;271(5642):223-5
pubmed: 622161
J Clin Pharmacol. 2015 Jan;55(1):10-6
pubmed: 25042595
Dig Liver Dis. 2000 Nov;32(8):691-8
pubmed: 11142579
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4554-61
pubmed: 20847294
EJNMMI Res. 2013 Aug 02;3(1):60
pubmed: 23915679
Nature. 2000 Aug 17;406(6797):775-81
pubmed: 10963607
Anaerobe. 2015 Aug;34:1-7
pubmed: 25817005
Annu Rev Microbiol. 2015;69:445-61
pubmed: 26488281
Antimicrob Agents Chemother. 2005 Dec;49(12):5190-1
pubmed: 16304203
Lancet Infect Dis. 2019 May;19(5):487-496
pubmed: 30885591
Environ Toxicol Pharmacol. 2017 Mar;50:1-10
pubmed: 28103518
J Clin Invest. 2014 Oct;124(10):4182-9
pubmed: 25036699
Molecules. 2014 May 27;19(6):6952-74
pubmed: 24871573
Chem Biol. 1999 Jun;6(6):353-9
pubmed: 10375541
JAMA. 2004 Jan 28;291(4):451-9
pubmed: 14747502
J Antimicrob Chemother. 2003 Feb;51(2):361-5
pubmed: 12562703
Nat Commun. 2014;5:3114
pubmed: 24445449
Dig Dis Sci. 1995 May;40(5):967-75
pubmed: 7729286
Chem Pharm Bull (Tokyo). 2002 May;50(5):688-91
pubmed: 12036033
Am J Infect Control. 2016 Jul 1;44(7):830-6
pubmed: 26905790
Antimicrob Agents Chemother. 2004 Jan;48(1):326-8
pubmed: 14693559